Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer

Sponsor

University College London (UCL) Cancer Institute (Other)

Overall Status

Unknown status

CT.gov ID

NCT01254591

Collaborator

(none)

500

Enrollment

Location

Study Details

Study Description

Brief Summary

RATIONALE: Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT) scanning before surgery, may help measure the extent of disease.

PURPOSE: This clinical trial is studying PET/CT scanning before surgery in patients with non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer Colorectal Cancer Esophageal Cancer Head and Neck Cancer Lung Cancer	Other: 18F-fluoromisonidazole Other: fluorescence angiography Other: laboratory biomarker analysis Procedure: infrared thermography Procedure: magnetic resonance imaging Procedure: therapeutic conventional surgery Radiation: [18F]-ML-10 Radiation: fludeoxyglucose F 18 Radiation: rubidium Rb-82	N/A

Detailed Description

OBJECTIVES:

To determine the ability of preoperative fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) scanning in assessing tumor angiogenesis in patients with potentially operable non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.
To determine the ability of preoperative fludeoxyglucose F 18 PET/CT scanning in assessing prognosis by means of measuring angiogenesis in these patients.

OUTLINE: All patients undergo fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) scanning for staging, tumor perfusion measurement/angiogenesis, and glucose metabolism. If staging confirms operable disease, then the patient proceeds to surgery as planned. Resected tumor tissue samples are examined for tumor angiogenesis in the various cancer types.

Some patients undergo a half-dose of rubidium Rb-82 or 18F-fluoromisonidazole or [18F]-ML-10 PET scan or fluorescence angiography. Patients with colorectal cancer undergo a CT scan for perfusion of the tumor after the staging PET/CT. Patients with breast cancer undergo infrared thermometry as well as a MRI scan for staging and to predict angiogenesis.

After completion of study therapy, patients are followed up at 1 month and then every 6 months for 5 years.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

500 participants

Primary Purpose:

Diagnostic

Official Title:

Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation

Study Start Date :

Nov 1, 2006

Anticipated Primary Completion Date :

Aug 1, 2013

Outcome Measures

Primary Outcome Measures

Clinical, radiological, and pathological correlation []
Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates) []

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

DISEASE CHARACTERISTICS:

Diagnosis of non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer
Potentially operable disease
Hormone receptor status not specified